BioSpace News Archive

Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, announced its unaudited consolidated financial results for the six months ended June 30, 2020

ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at the LD 500 investor conference.

Madrigal Pharmaceuticals, Inc. announced that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European Association for the Study of the Liver, secondary analyses of data from its Phase 2 NASH study with MGL-3196 will be presented.

Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it has filed a submission seeking clearance of KidneyIntelX™ with the U.S. Food and Drug Administration.

Altimmune, Inc. announced a preclinical data presentation on ALT-801, its balanced and long-acting GLP-1/glucagon receptor dual agonist under development for NASH, at the Digital International Liver Congress™ 2020, the 55th Annual Meeting of the European Association for the Study of the Liver, to be held virtually from August 27, 2020 to August 29, 2020.

Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

Proof of concept would validate platform for multiple indications and therapeutic alternatives in infectious diseases and others

Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise.

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, announced that the IMV’s executive management team will participate at four upcoming virtual investor conferences in September:

COVID-19 pandemic has caused significant decline in colonoscopies and underscores the value of less invasive screening options for colorectal cancer (CRC)